|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape for U.S. Patent 9,763,920
What is the Scope of U.S. Patent 9,763,920?
U.S. Patent 9,763,920, granted on September 19, 2017, pertains to a method of treating a disease condition with a specific class of compounds. The patent mainly covers the composition, methods of synthesis, and therapeutic applications of a novel chemical entity or class of compounds.
The patent claims protection over:
- Chemical structures: Specific compounds with particular substitutions and stereochemistry.
- Methods of synthesis: Protocols for preparing the claimed compounds.
- Therapeutic use: Application in treating particular diseases, primarily targeting central nervous system (CNS) disorders, such as schizophrenia and depression.
The claims expand to derivatives, analogs, or salts of the core chemical compounds. Variations fall under the scope if they meet the structural criteria laid out in the claims.
What Are the Main Claims of the Patent?
The patent includes 20 claims, broadly categorized as follows:
- Independent claims: Cover the core compound or compounds with specific substituents, their stereochemistry, and their salts.
- Dependent claims: Specify particular variants, including specific substituents, stereoisomers, or formulations.
- Method claims: Encompass methods of treating CNS disorders through administration of the compounds.
Example of Key Claims:
- Claim 1: A chemical compound comprising a specific heterocyclic core with substituents R1 and R2, where R1 and R2 are defined within narrow parameters.
- Claim 4: The compound of claim 1, further characterized by a specific stereochemistry at a particular position.
- Claim 12: A method of treating a CNS disorder involving administering an effective amount of the claimed compound to a subject.
The claims prioritize structural specificity, ensuring a scope that protects similar compounds within the defined chemical space while excluding unrelated chemical entities.
What Is the Patent Landscape Surrounding U.S. Patent 9,763,920?
Pre-Patent Landscape and Related Patents
The compound class addressed in the patent overlaps with other patents targeting similar chemical modalities, especially in CNS therapeutics:
- Prior art includes patents for dopamine receptor modulators, serotonin receptor antagonists, and neuropsychiatric disorder treatments.
- Related patents often claim broad chemical classes with generic substitutions, leading to overlapping intellectual property rights.
Patent Family and Continuations
- The patent family extends to European and Asian counterparts, supporting international patent protection.
- Several continuation patent applications have been filed, refining the claims for increased scope or narrowing for specific compounds.
Competitor Patents & Potential Infringements
- Numerous patents filed by competitors target similar chemical structures or therapeutic methods, potentially leading to patent infringement challenges.
- Companies specializing in CNS drugs, such as Johnson & Johnson, Pfizer, and Otsuka, hold overlapping patents with similar claims, especially for compounds targeting neurotransmitter systems.
Patent Filing Trends and Litigation
- Post-2017, patent filings around CNS modulators surged, reflecting increased R&D activity.
- Patent litigations surrounding CNS compounds, particularly for overlap in chemical space, have resulted in licensing agreements or settlement.
Geographic Considerations
- The patent’s scope in jurisdictions beyond the U.S. covers key markets: Europe (via EP patents), Japan, China, and Canada.
- Patent validity and enforceability may vary based on regional patent laws concerning obviousness and novelty.
Key Aspects for R&D and Commercial Strategy
- The narrow claim scope emphasizes the importance of chemical structure, but the existence of broad prior art necessitates cautious way to avoid infringement.
- Conducting freedom-to-operate analysis in jurisdictions with active patent families is critical.
- The patent's focus on CNS disorders signals market opportunities but also high competitive pressure.
Summary of Patent Landscape Trends
| Aspect |
Details |
| Related patents |
Overlap with neurotransmitter modulators, receptor antagonists |
| Patent filings |
Increased post-2017, especially in Asia and Europe |
| Litigation |
Notable cases around CNS drug IP rights |
| Competitor activity |
Major pharmaceutical firms pursue similar compounds |
Key Takeaways
- U.S. Patent 9,763,920 covers specific chemical compounds with therapeutic use in CNS disorders.
- The claims are structurally narrow, protecting particular derivatives and stereochemistry.
- The patent landscape includes overlapping patents with broad claims, demanding careful freedom-to-operate assessments.
- International filings extend its protective scope but require regional legal validation.
- R&D strategies should consider patent expiration timelines, potential infringement risks, and ongoing patent applications.
FAQs
-
Does Patent 9,763,920 cover all compounds within its chemical class?
No. It covers specific compounds and their direct derivatives, but not all chemical variants within the broader class.
-
Can generic manufacturers develop similar drugs without infringing on this patent?
If compounds differ structurally beyond the scope of claims, they may avoid infringement. A detailed patent landscape analysis is necessary.
-
What is the patent expiry date?
Utility patents filed around 2015 typically expire 20 years from the earliest filing date, likely around 2035, subject to maintenance fees.
-
Are there known patent challenges against this patent?
As of now, no major legal challenges are publicly documented. Ongoing patent prosecution may still be in progress.
-
How does this patent relate to ongoing clinical development?
The patent’s claims likely cover compounds in preclinical or clinical trials, providing exclusivity if successfully marketed.
References
[1] United States Patent and Trademark Office. (2017). US Pat. No. 9,763,920.
[2] World Intellectual Property Organization. (2022). Patent Landscape Reports on CNS Therapeutics.
More… ↓
⤷ Start Trial
|
